With the first half of 2026 officially in the books and another earnings season about to begin, a key question hangs over the biopharma industry: Will the good times continue?
With the first half of 2026 officially in the books and another earnings season about to begin, a key question hangs over the biopharma industry: …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in…
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Biopharma dealmaking rebounds in Q2 2026: M&A nears $80B and licensing/R&D alliances hit a 5-year record $83B, per DealForma.
Pharmaceutical companies are hungry to make deals, and they’re making more than they have in years.
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune…
With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since 2020,…
